​
​

Bicycle Therapeutics (BCYC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BCYC Stock Forecast

Bicycle Therapeutics stock forecast is as follows: an average price target of $54.40 (represents a 168.51% upside from BCYC’s last price of $20.26) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

BCYC Price Target

The average price target for Bicycle Therapeutics (BCYC) is $54.40 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $76.00 to $28.00. This represents a potential 168.51% upside from BCYC's last price of $20.26.

BCYC Analyst Ratings

Buy

According to 9 Wall Street analysts, Bicycle Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BCYC stock is 0 'Strong Buy' (0.00%), 8 'Buy' (88.89%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Bicycle Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Jay OlsonOppenheimer--89.57%136.92%
Oct 24, 2024Kalpit PatelB.Riley Financial--10.58%38.20%
Sep 16, 2024Swayampakula RamakanthH.C. Wainwright--103.55%171.47%
Oct 07, 2021Edward TenthoffPiper Sandler--56.09%275.12%
Oct 07, 2021Anthony ButlerRoth Capital--33.50%220.83%
Row per page
Go to

The latest Bicycle Therapeutics stock forecast, released on Oct 24, 2024 by Jay Olson from Oppenheimer, set a price target of $48.00, which represents a 89.57% increase from the stock price at the time of the forecast ($25.32), and a 136.92% increase from BCYC last price ($20.26).

Bicycle Therapeutics Price Target by Period

1M3M12M
# Anlaysts233
Avg Price Target$38.00$43.67$43.67
Last Closing Price$20.26$20.26$20.26
Upside/Downside87.56%115.55%115.55%

In the current month, the average price target of Bicycle Therapeutics stock is $38.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 87.56% increase as opposed to Bicycle Therapeutics's last price of $20.26. This month's average price target is down -12.98% compared to last quarter, and down -12.98% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024Leerink PartnersOutperformOutperformHold
Oct 24, 2024RBC CapitalMarket OutperformMarket OutperformHold
Oct 24, 2024OppenheimerUnderperformUnderperformHold
Oct 24, 2024H.C. WainwrightBuyBuyHold
Oct 24, 2024OppenheimerOutperformOutperformHold
Sep 16, 2024Cowen & Co.BuyBuyHold
Sep 16, 2024H.C. WainwrightBuyBuyHold
Sep 06, 2024RBC CapitalBuyBuyHold
Sep 06, 2024OppenheimerUnderperformUnderperformHold
Sep 05, 2024RBC CapitalOutperformInitialise
Row per page
Go to

Bicycle Therapeutics's last stock rating was published by Leerink Partners on Oct 31, 2024. The company gave BCYC a "Outperform" rating, the same as its previous rate.

Bicycle Therapeutics Financial Forecast

Bicycle Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Revenue---------$5.35M$11.40M$4.90M$3.19M$3.04M$4.38M$3.86M$3.77M$4.33M$1.78M$1.81M$3.85M$3.84M$1.57M$1.13M$5.28M$614.00K$1.52M
Avg Forecast$5.82M$5.38M$6.52M$5.56M$5.47M$6.82M$6.13M$6.06M$6.98M$12.94M$5.78M$3.88M$3.55M$5.70M$3.69M$4.46M$5.52M$5.75M$2.31M$1.81M$3.66M$2.73M$2.36M$3.50M$1.48M$1.32M$1.03M
High Forecast$9.90M$9.15M$11.09M$9.46M$8.84M$6.88M$6.13M$6.06M$15.75M$13.02M$9.82M$6.59M$6.04M$5.70M$3.69M$4.46M$5.52M$5.75M$2.31M$1.81M$3.66M$2.73M$2.36M$3.50M$1.48M$1.32M$1.03M
Low Forecast$2.92M$2.70M$3.27M$2.79M$1.99M$6.76M$6.13M$6.06M$2.99M$12.87M$2.89M$1.94M$1.78M$5.70M$3.69M$4.46M$5.52M$5.75M$2.31M$1.81M$3.66M$2.73M$2.36M$3.50M$1.48M$1.32M$1.03M
# Analysts11139433613665551112111099876555
Surprise %---------0.41%1.97%1.26%0.90%0.53%1.19%0.86%0.68%0.75%0.77%1.00%1.05%1.41%0.67%0.32%3.57%0.47%1.47%

Bicycle Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $6.98M, with a low forecast of $2.99M, and a high forecast of $15.75M. BCYC's average Quarter revenue forecast represents a 30.48% increase compared to the company's last Quarter revenue of $5.35M (Sep 23).

Bicycle Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts11139433613665551112111099876555
EBITDA---------$-50.80M$-41.04M$-38.87M$-29.57M$-26.70M$-26.39M$-26.63M$-17.56M$-13.93M$-16.91M$-15.68M$-16.72M$-10.27M$-11.90M$-11.13M$-4.27M$-9.57M$-9.85M
Avg Forecast$-5.82M$-5.38M$-6.52M$-5.56M$-5.47M$-6.82M$-6.13M$-6.06M$-6.98M$-12.94M$-5.78M$-3.88M$-3.55M$-5.70M$-3.69M$-16.91M$-5.52M$-5.75M$-2.31M$-15.24M$-3.66M$-2.73M$-2.36M$-77.38M$-1.48M$-1.32M$-10.95M
High Forecast$-2.92M$-2.70M$-3.27M$-2.79M$-1.99M$-6.76M$-6.13M$-6.06M$-2.99M$-12.87M$-2.89M$-1.94M$-1.78M$-5.70M$-3.69M$-13.53M$-5.52M$-5.75M$-2.31M$-12.19M$-3.66M$-2.73M$-2.36M$-61.90M$-1.48M$-1.32M$-8.76M
Low Forecast$-9.90M$-9.15M$-11.09M$-9.46M$-8.84M$-6.88M$-6.13M$-6.06M$-15.75M$-13.02M$-9.82M$-6.59M$-6.04M$-5.70M$-3.69M$-20.29M$-5.52M$-5.75M$-2.31M$-18.29M$-3.66M$-2.73M$-2.36M$-92.85M$-1.48M$-1.32M$-13.14M
Surprise %---------3.93%7.11%10.03%8.32%4.68%7.16%1.57%3.18%2.42%7.33%1.03%4.57%3.77%5.04%0.14%2.89%7.25%0.90%

undefined analysts predict BCYC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bicycle Therapeutics's previous annual EBITDA (undefined) of $NaN.

Bicycle Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts11139433613665551112111099876555
Net Income---------$-49.90M$-42.60M$-39.06M$-29.98M$-28.35M$-26.83M$-27.56M$-18.04M$-14.68M$-17.91M$-16.19M$-17.43M$-10.14M$-12.12M$-11.32M$-4.41M$-9.48M$-10.22M
Avg Forecast$-63.88M$-65.54M$-61.40M$-60.71M$-59.53M$-54.95M$-76.42M$-86.31M$-85.09M$-82.84M$-82.77M$-74.36M$-73.05M$-46.79M$-44.12M$-17.43M$-32.00M$-31.77M$-36.97M$-15.73M$-24.57M$-26.91M$-24.73M$-78.75M$-27.24M$-30.03M$-11.35M
High Forecast$-22.46M$-23.05M$-21.59M$-21.35M$-42.11M$-19.32M$-26.87M$-30.35M$-46.35M$-16.29M$-29.11M$-26.15M$-25.69M$-46.79M$-44.12M$-13.94M$-32.00M$-31.77M$-36.97M$-12.59M$-24.57M$-26.91M$-24.73M$-63.00M$-27.24M$-30.03M$-9.08M
Low Forecast$-122.10M$-125.27M$-117.36M$-116.04M$-73.32M$-105.04M$-146.06M$-164.96M$-114.14M$-130.99M$-158.20M$-142.13M$-139.63M$-46.79M$-44.12M$-20.92M$-32.00M$-31.77M$-36.97M$-18.88M$-24.57M$-26.91M$-24.73M$-94.50M$-27.24M$-30.03M$-13.62M
Surprise %---------0.60%0.51%0.53%0.41%0.61%0.61%1.58%0.56%0.46%0.48%1.03%0.71%0.38%0.49%0.14%0.16%0.32%0.90%

Bicycle Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCYC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Bicycle Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts11139433613665551112111099876555
SG&A---------$16.28M$15.18M$14.49M$10.68M$10.25M$11.82M$16.85M$8.72M$8.27M$7.35M$8.14M$10.85M$7.15M$6.20M$5.00M$3.40M$4.79M$2.97M
Avg Forecast$14.29M$13.21M$16.01M$13.65M$13.43M$16.75M$15.05M$14.89M$17.15M$31.78M$14.18M$9.52M$8.72M$14.01M$9.06M$10.96M$13.57M$14.12M$5.67M$4.45M$8.98M$6.69M$5.80M$8.61M$3.63M$3.24M$2.54M
High Forecast$24.31M$22.48M$27.24M$23.23M$21.72M$16.90M$15.05M$14.89M$38.69M$31.97M$24.13M$16.20M$14.84M$14.01M$9.06M$10.96M$13.57M$14.12M$5.67M$4.45M$8.98M$6.69M$5.80M$8.61M$3.63M$3.24M$2.54M
Low Forecast$7.16M$6.62M$8.03M$6.84M$4.89M$16.59M$15.05M$14.89M$7.34M$31.60M$7.11M$4.77M$4.37M$14.01M$9.06M$10.96M$13.57M$14.12M$5.67M$4.45M$8.98M$6.69M$5.80M$8.61M$3.63M$3.24M$2.54M
Surprise %---------0.51%1.07%1.52%1.22%0.73%1.31%1.54%0.64%0.59%1.30%1.83%1.21%1.07%1.07%0.58%0.93%1.48%1.17%

Bicycle Therapeutics's average Quarter SG&A projection for Dec 23 is $17.15M, based on 6 Wall Street analysts, with a range of $7.34M to $38.69M. The forecast indicates a 5.34% rise compared to BCYC last annual SG&A of $16.28M (Sep 23).

Bicycle Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts11139433613665551112111099876555
EPS---------$-0.00$-1.41$-1.30$-1.01$-0.96$-0.90$-0.93$-0.63$-0.59$-0.74$-0.73$-0.83$-0.52$-0.67$-0.63$-0.25$-0.53$-1.40
Avg Forecast$-0.93$-0.95$-0.89$-0.88$-0.86$-0.80$-1.11$-1.25$-1.23$-1.20$-1.20$-1.08$-1.06$-0.90$-0.85$-0.68$-0.62$-0.61$-0.71$-0.71$-0.47$-0.52$-0.48$-0.37$-0.52$-0.58$-0.46
High Forecast$-0.33$-0.33$-0.31$-0.31$-0.61$-0.28$-0.39$-0.44$-0.67$-0.24$-0.42$-0.38$-0.37$-0.90$-0.85$-0.68$-0.62$-0.61$-0.71$-0.71$-0.47$-0.52$-0.48$-0.37$-0.52$-0.58$-0.46
Low Forecast$-1.77$-1.82$-1.70$-1.68$-1.06$-1.52$-2.12$-2.39$-1.65$-1.90$-2.29$-2.06$-2.02$-0.90$-0.85$-0.68$-0.62$-0.61$-0.71$-0.71$-0.47$-0.52$-0.48$-0.37$-0.52$-0.58$-0.46
Surprise %---------0.00%1.18%1.21%0.95%1.07%1.06%1.37%1.02%0.97%1.04%1.03%1.76%1.00%1.41%1.71%0.48%0.92%3.08%

According to undefined Wall Street analysts, Bicycle Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCYC previous annual EPS of $NaN (undefined).

Bicycle Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ANEBAnebulo Pharmaceuticals--300.00%Buy
ACRVAcrivon Therapeutics--238.98%Buy
CCCCC4 Therapeutics--236.66%Buy
FIXXQ32 Bio--190.32%Buy
STOKStoke Therapeutics--171.52%Buy
BCYCBicycle Therapeutics--168.51%Buy
CGEMCullinan Oncology--157.77%Buy
MLYSMineralys Therapeutics--152.74%Buy
ANABAnaptysBio--145.63%Buy
IGMSIGM Biosciences--128.68%Buy
ADAGAdagene--121.24%Buy
KROSKeros Therapeutics--90.56%Buy
ORICORIC Pharmaceuticals--86.40%Buy
IDYAIDEAYA Biosciences--75.11%Buy
MRUSMerus--72.84%Buy
MGTXMeiraGTx--52.03%Buy

BCYC Forecast FAQ

Is Bicycle Therapeutics a good buy?

Yes, according to 9 Wall Street analysts, Bicycle Therapeutics (BCYC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 88.89% of BCYC's total ratings.

What is BCYC's price target?

Bicycle Therapeutics (BCYC) average price target is $54.4 with a range of $28 to $76, implying a 168.51% from its last price of $20.26. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Bicycle Therapeutics stock go up soon?

According to Wall Street analysts' prediction for BCYC stock, the company can go up by 168.51% (from the last price of $20.26 to the average price target of $54.4), up by 275.12% based on the highest stock price target, and up by 38.20% based on the lowest stock price target.

Can Bicycle Therapeutics stock reach $30?

BCYC's average twelve months analyst stock price target of $54.4 supports the claim that Bicycle Therapeutics can reach $30 in the near future.

What is Bicycle Therapeutics's current price target trend?

2 Wall Street analysts forecast a $38 price target for Bicycle Therapeutics (BCYC) this month, up 87.56% from its last price of $20.26. Compared to the last 3 and 12 months, the average price target increased by 115.55% and increased by 115.55%, respectively.

What are Bicycle Therapeutics's analysts' financial forecasts?

Bicycle Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $24.48M (high $27.92M, low $20.94M), average EBITDA is $-24.481M (high $-20.941M, low $-27.917M), average net income is $-277M (high $-119M, low $-489M), average SG&A $60.12M (high $68.56M, low $51.43M), and average EPS is $-4.018 (high $-1.72, low $-7.094). BCYC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $23.28M (high $39.6M, low $11.67M), average EBITDA is $-23.28M (high $-11.669M, low $-39.6M), average net income is $-252M (high $-88.451M, low $-481M), average SG&A $57.17M (high $97.25M, low $28.66M), and average EPS is $-3.646 (high $-1.282, low $-6.969).

Did the BCYC's actual financial results beat the analysts' financial forecasts?

Based on Bicycle Therapeutics's last annual report (Dec 2022), the company's revenue was $14.46M, which missed the average analysts forecast of $17.41M by -16.92%. Apple's EBITDA was $-111M, beating the average prediction of $-29.856M by 271.44%. The company's net income was $-113M, missing the average estimation of $-181M by -37.86%. Apple's SG&A was $49.51M, beating the average forecast of $42.75M by 15.79%. Lastly, the company's EPS was $-3.8, beating the average prediction of $-3.487 by 8.96%. In terms of the last quarterly report (Sep 2023), Bicycle Therapeutics's revenue was $5.35M, missing the average analysts' forecast of $12.94M by -58.65%. The company's EBITDA was $-50.797M, beating the average prediction of $-12.942M by 292.51%. Bicycle Therapeutics's net income was $-49.898M, missing the average estimation of $-82.843M by -39.77%. The company's SG&A was $16.28M, missing the average forecast of $31.78M by -48.77%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.201 by -99.89%